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Abstract The implantation of cardiac pacemakers has be-
come a well-established therapy for conduction disorders
and sinus node dysfunction. In many countries pacemaker
registries have been initiated in order to collect information
on patient characteristics, trends in numbers and the types
of pacemakers used, to identify problematic devices, and
for safety monitoring. For this utilisation study the Central
Pacemaker Patients Registration (CPPR) from the Nether-
lands Pacemaker Registry Foundation (CPPR-SPRN) con-
taining data collected for more than 20 years was used.
During this period nearly 97,000 first pacemakers were im-
planted. Analyses show an increase in the rate of implanted
devices. The change in pacemaker type from VVI to DDD,
followed by biventricular stimulation, is reflected by the
number of simultaneously implanted leads, which is partly
a consequence of cardiac resynchronisation therapy. Our
data demonstrate that indications for implantation and type
of pacemaker are comparable with other European coun-
tries.
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Introduction
Advantages of cardiac pacing have been established in the
past decades for conventional indications such as conduc-
tion disorders, and with new applications for treatment of
arrhythmias and heart failure being added, clinical inves-
tigation is ongoing. Implantation of cardiac pacemakers
has prolonged the lives and improved the quality of life of
many patients [1–3]. Despite these advantages, implanta-
tion of devices is also inevitably associated with compli-
cations and may be prone to product defects. This was
illustrated by several major cases and recalls in the past,
such as the Accufix leads for cardiac pacemakers [4–7].
In many countries device registries were initiated by in-
dividual cardiologists or national societies in order to gain
insight into patient characteristics, trends in numbers and
the types of pacemakers used, to inform participating cen-
tres about problematic devices, and to exchange informa-
tion between countries [8–10]. However, most of these
registries were restricted to a limited number of hospitals
or geographical areas. In the Netherlands, registration with
the intention to record every pacemaker implanted in Dutch
hospitals was initiated in 1982. This registry, maintained by
the Netherlands Pacemaker Registry Foundation (SPRN),
was kept until 2008 after which the Netherlands Society of
Cardiology started a new registration: the Dutch ICD and
Pacemaker Registration (DIPR), which was recently inte-
grated into the overarching National Cardiovascular Data
Registry (NCDR).
The objective of the current analysis was to study
changes in the utilisation of cardiac pacemakers for new
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implantations over a period of more than 20 years in
a country with the nearly nationwide pacemaker registry
CPPR-SPRN.
Methods
Setting
Data were retrieved from the Central Pacemaker Patients
Registration (CPPR) from the Netherlands Pacemaker Reg-
istry Foundation (CPPR-SPRN). In 1982, CPPR-SPRN was
established and the computerised Central Pacemaker Pa-
tients Registration was started. The aims of the registry
were to get an overview of: 1) patient and implant charac-
teristics; 2) trends in types of pacemakers and leads; and
3) the annual number of implants per clinic and nationwide.
Furthermore, the objectives of the registry were to inform
the participating clinics and recipients about quality issues
with pacemakers and leads, to exchange information with
other European countries, and to increase indirect patient
care by furnishing information to clinics about pacemak-
ers implanted elsewhere and to patients about pacemaker
centres in other countries.
Cardiologists and pacemaker technicians were requested
to register data on the patient, device and leads on the pace-
maker card. Each recipient of a pacemaker was registered
in the database. Data on symptoms, indication and diagno-
sis, brand of pacemaker and leads, type, follow-up visits,
explantation, hospital transfer and death were registered
according to European Registry Guidelines established in
1982 and later. When CPPR-SPRN ended its registration
activities in December 2007, data on 174,405 first implan-
tations and replacements, with 204,920 leads, had been
recorded for 136,342 patients during 25 years [8].
Monitoring and validation of data
Until 1989, data were centrally registered by sending a car-
bon copy of the pacemaker card to the registry. From 1989
onwards, digitalised registration was used with automatic
communication between the central registration computer
and the local computer of the implanting centre. During
the daily conversions into the database, multiple checks
were performed on: missing data, conformation with al-
ready stored information and plausibility [11]. Addition-
ally, the data were periodically returned to the clinics for
correction purposes. A validation process in order to obtain
better insight into the quality of the database was performed
in 1997 [12].
Cohort
Based on the available data, an inception cohort of patients
was formed containing all first implanted pacemakers dur-
ing the period 1 January 1984 until 1 January 2006. A total
of 353 implantations were excluded because of inconsisten-
cies in the registered data, such as a new implantation being
registered after the supposed date of death of a patient, or
the same pacemaker registered more than once with dif-
ferent explantation dates, leaving 96,900 first implantations
for analysis.
At the start of the registration in 1984, 120 hospitals
participated, some of which were sub locations of the same
hospital but participated independently. During the study
period several locations and/or hospitals merged and the
registry was continued under one account, leaving 101 par-
ticipants in the registry. General population data were ob-
tained from Statistics Netherlands (CBS, www.cbs.nl/en-
GB/).
Analysis
We computed straightforward descriptive statistics for the
aetiology, pacemaker types, and the prevalences of symp-
toms and ECG characteristics as percentages of all first im-
plantations. For implantation rates, we calculated Poisson
intervals. For the comparison of normally distributed con-
tinuous determinants, we used independent samples T-tests
while categorical determinants were compared with chi-
square statistics. All statistical analyses were performed
in IBM SPSS Statistics version 20.0 (IBM Corp., Somers,
New York, USA).
Results
Between 1 January 1984 and 1 January 2006, 96,900 first
pacemakers were implanted (Table 1). This corresponds
to an average number of implantations of more than 4600
devices per year, varying from a total of 3236 first implan-
tations in 1984 (225 implants per million inhabitants) to
6901 first implantations in 2005 (423 implants per million
inhabitants).
One hospital performed nearly 4000 first implantations
during the study period, which is approximately 4 % of
the total number of first implantations. One hospital im-
planted more than 2600 first pacemakers (2.7 %), 5 hos-
pitals implanted between 1900 and 2500 pacemakers each
(2–2.5 %), another 36 hospitals implanted between 900 and
1900 pacemakers each (1–2 %). All other hospitals each
implanted less than 1 % of the total number of first pace-
makers. Eight of these hospitals did not participate in the
registration until the early 1990s. Six hospitals did not start
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Table 1 Baseline characteristics of the patients at implantation of first pacemaker
Womena Mena p-value for
differenceb
All first implanta-
tions
Total number of first implantations 45,661 (47,1) 51,164 (52.8) <0.001c 96,900
Mean age, years (SD) 74.6 (12.6) 71.4 (13.2) <0.001 72.9 (13.0)
Median age, years 77.0 74.0 – 75.0
Age ≥60 years, n (%) 41,457 (90.8) 43,637 (85.3) <0.001 85,165 (87.9)
Age ≥80 years, n (%) 17,489 (38.3) 12,208 (23.9) <0.001 31,569 (32.6)
ECG, n (%):
Sick sinus syndrome 20,166 (44.2) 20,847 (40.7) <0.001 41,026 (42.3)
Heart block 17,612 (38.6) 20,050 (39.2) 0.049 37,682 (38.9)
Bundle branch block 1537 (3.4) 2582 (5.0) <0.001 4121 (4.3)
Normal sinus rhythm
(with or without abnormal EPSd) or not documented
940 (2.1) 1164 (2.3) 0.021 2104 (2.2)
Other 541 (1.2) 691 (1.4) 0.022 1232 (1.3)
Unknown/uncoded/unspecified 4865 (10.7) 5830 (11.4) <0.001 10,735 (11.1)
Symptoms, n (%):
Syncope 13,004 (28.5) 14,651 (28.6) 0.592 27,672 (28.6)
Dizzy spells 12,749 (27.9) 12,973 (25.4) <0.001 25,728 (26.6)
Bradycardia 9,485 (20.8) 10,908 (21.3) 0.037 20,398 (21.1)
Dyspnoea/heart failure 2396 (5.2) 3064 (6.0) <0.001 5462 (5.6)
None/prophylactic 751 (1.6) 1132 (2.2) <0.001 1884 (1.9)
Tachycardia 866 (1.9) 876 (1.7) 0.031 1743 (1.8)
Other 215 (0.5) 267 (0.5) 0.260 483 (0.5)
Unknown/uncoded/unspecified 6195 (13.6) 7293 (14.3) 0.002 13,530 (14.0)
Aetiology, n (%):
Conduction tissue disease 5219 (11.4) 5401 (10.6) n.c. 10,623 (11.0)
Ischaemic 2100 (4.6) 2718 (5.3) n.c. 4818 (5.0)
Therapy induced 1603 (3.5) 1978 (3.9) n.c. 3583 (3.7)
Cardiomyopathy 1170 (2.6) 1400 (2.7) n.c. 2572 (2.7)
Post myocardial infarction 716 (1.6) 1528 (3.0) n.c. 2244 (2.3)
Congenital 394 (0.9) 348 (0.7) n.c. 742 (0.8)
Other 182 (0.4) 446 (0.9) n.c. 628 (0.6)
Unknown/uncoded/unspecified, n (%) 34,277 (75.1) 37,345 (73.0) n.c. 71,690 (74.0)
aFor 75 patients the sex is unknown, for 38 males and 22 females age is unknown
bP-value was not calculated for aetiology because of large proportion of missing data (n.c.)
cFor 1995–2005
dEPS electrophysiological study
until the late 1990s or early 2000s. Two hospitals implanted
less than 10 first pacemakers per year. Most pacemakers per
1000 inhabitants were implanted in the province of Gronin-
gen, followed by the provinces of Overijssel and Limburg
(Fig. 1 and Table 2).
The cohort comprised 52.8 % men (n = 51,164). Starting
in 1995 the number of implantations in men was signifi-
cantly higher than in women (p < 0.001) in each following
year. In the period before 1995 the number of implants in
men was only significantly higher in the years 1985, 1986
and 1992 (Table 1, Fig. 2). Mean age for the total cohort
was 72.9 years (SD 13.0). The mean age at first implanta-
tion increased from 71.1 in 1984 to 72.3 in 2005 for men
(mean difference 1.2 years, p = 0.003) and from 72.8 to 75.1
for women (mean difference 2.3 years, p < 0.001). The ma-
jority of the patients were over 60 years of age (87.9 %) and
pacemakers were most often implanted in the age group of
60 to 80 year olds. The percentage of first implantations in
octogenarians and nonagenarians is constant over the years.
However, first implantations in these groups have been in-
creasing since 2002. The most common indications were
sick sinus syndrome (n = 41,026; 42.3 %) and heart block
(n = 37,682; 38.9 %). This did not change over the years
(Fig. 3). The number of pacemaker implantations for both
sick sinus syndrome and bundle branch block significantly
differed between men and women (p < 0.001). All baseline
characteristics are provided in Table 2.
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Fig. 1 Number of first implantations per 1000 inhabitants per province. (1984 and 1985 excluded to create equal time periods, additionally no
population data are available for these years for Flevoland)
Fig. 2 Number of first implantations per 100,000 inhabitants by sex
Pacemakers of 18 different manufacturers were im-
planted between 1984 and 2005. The ventricular pacing
and sensing (VVI) and dual-chamber pacing and sensing,
rate response (DDDR) types were the most commonly
used pacemakers: 34.3 % and 23.1 %, respectively (Ta-
ble 3). The other types, ventricular pacing and sensing,
rate response (VVIR, 15.2 %) and dual-chamber pacing
and sensing (DDD, 16.1 %), were used less often. How-
ever, during the early 1990s implantation of pacemaker
types changed markedly from a mainly VVI type (single
chamber systems) to a DDDR type (dual chamber sys-
tems) as depicted in Fig. 4. At least 138,225 leads were
implanted with the 96,900 first pacemakers. In two thirds
Fig. 3 Indication for first pacemaker implantation, adjusted for num-
ber of implantations per year. (BBB bundle branch block; SSS sick
sinus syndrome; normal sinus rhythm with or without abnormal elec-
trophysiological study)
of the cases the leads were placed in the ventricle. For
1024 implantations (1 %) no leads were registered. For
83 % of these implantations the type of pacemaker was
also not registered. More than 80 % of these pacemakers
were implanted during the last 5 years of the study period.
Additionally, after the introduction of cardiac resynchro-
nisation therapy (CRT) around 1995 [13], the use of biven-
tricular pacing increased between 2000 and 2005. This
change of pacemaker type is also reflected by the num-
ber of first implantations with three leads (n = 1269), 914
(72.3 %) of which for the indication dyspnoea/heart failure
and 65 (5.1 %) for bradycardia. The other first implanta-
tions with three leads were for various other indications
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Table 2 Number of implants per 1000 inhabitants and distribution of population >60 years over provinces
1986–1990a 1991–1995 1996–2000 2001–2005
Number of
implants per
1000 inhabitants
per province
(95 % CI)
% of
popu-
lation
>60 yearsb
Number of
implants per
1000 inhabitants
per province
(95 % CI)
% of
popu-
lation
>60 years
Number of
implants per
1000 inhabitants
per province
(95 % CI)
% of
popu-
lation
>60 yearsb
Number of
implants per
1000 inhabitants
per province
(95 % CI)
% of
popu-
lation
>60 years
Drenthe 0.61 (0.54–0.69) 3.1 0.96 (0.87–1.05) 3.2 1.36 (1.25–1.47) 3.3 2.25 (2.12–2.38) 3.4
Flevoland 0.64 (0.54–0.76) 0.9 0.76 (0.65–0.87) 1.1 0.55 (0.47–0.63) 1.3 0.97 (0.87–1.07) 1.4
Friesland 1.17 (1.09–1.26) 4.3 1.15 (1.06–1.24) 4.2 1.34 (1.25–1.43) 4.1 1.73 (1.63–1.83) 4.2
Gelderland 0.87 (0.83–0.92) 11.9 0.93 (0.89–0.97) 12.0 1.07 (1.02–1.12) 12.1 1.31 (1.26–1.36) 12.2
Groningen 1.36 (1.26–1.46) 4.1 1.62 (1.51–1.73) 3.9 2.01 (1.89–2.13) 3.8 2.53 (2.40–2.66) 3.7
Limburg 1.47 (1.40–1.55) 7.3 1.52 (1.45–1.59) 7.5 1.60 (1.53–1.67) 7.8 2.15 (2.07–2.24) 7.9
Noord-
Brabant
1.13 (1.09–1.13) 12.8 1.24 (1.19–1.29) 13.4 1.44 (1.39–1.49) 14.2 1.76 (1.71–1.81) 14.7
Noord-
Holland
1.09 (1.05–1.13) 16.7 1.20 (1.16–1.24) 16.2 1.46 (1.41–1.51) 15.7 2.01 (1.96–2.06) 15.5
Overijssel 1.36 (1.29–1.44) 6.8 1.66 (1.58–1.74) 6.8 1.87 (1.79–1.95) 6.8 2.37 (2.28–2.46) 6.8
Utrecht 1.13 (1.07–1.20) 6.3 1.28 (1.21–1.35) 6.4 1.46 (1.39–1.53) 6.4 1.72 (1.64–1.80) 6.4
Zeeland 1.41 (1.30–1.54) 2.8 1.45 (1.33–1.57) 2.8 1.58 (1.45–1.71) 2.8 1.90 (1.76–2.04) 2.8
Zuid-
Holland
1.34 (1.30–1.38) 22.9 1.45 (1.41–1.49) 22.3 1.47 (1.43–1.51) 21.7 2.04 (1.99–2.09) 21.0
a1984 and 1985 excluded to create equal time periods, additionally no population data are available for these years for Flevoland
bCalculated over the years 1988–1990, no population data available for 1986 and 1987
Table 3 Type of pacemakers implanted in the period 1984–2005 in
the Netherlands
First pacemaker
N = 96,900
Pacemaker type N (%)
VVI 33,241 (34.3)
VVIR 14,704 (15.2)
DDD 15,636 (16.1)
DDDR 22,424 (23.1)
AAI 1500 (1.4)
AAIR 1350 (1.4)
VDD 2677 (2.8)
VDDR 1123 (1.2)
Biventricular pacing 1269 (1.3)
Unknown 2,976 (3.1)
(n = 96, 7.6 %) and unknown, uncoded or unspecified indi-
cations (n = 190, 15.0 %).
Discussion
In the Netherlands the SPRN registry was operational for
more than 20 years to collect pacemaker implantations with
nearly complete nationwide coverage; almost 97,000 pa-
tients received a pacemaker for the first time between 1984
and 2006. The registry showed that the number of im-
planted pacemakers has increased steadily over the past few
Fig. 4 Type of pacemaker at first implantation
decades. This increase continued in later years (2003–2012)
[14].
The number of first implantations per million Dutch in-
habitants was below the European average: 314, 294, and
532 implantations per million inhabitants in 2001, 2005,
and 2009, respectively, compared with an average of 390,
475, and 552 implantations per million inhabitants in Eu-
rope [15–17]. Stofmeel and colleagues [18] also reported
that the Netherlands had a smaller number of implantations
compared with other European countries over the period
1984–1997. This may be a consequence of reluctance to
use pacemakers for indications for which there was limited
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evidence at that time, such as asymptomatic total AV-block
or asymptomatic second degree AV-block, type Wencke-
bach, or syncope which is not proven to be a consequence
of a total AV-block in patients with a bifascicular or tri-
fascicular block and other causes for syncope cannot be
excluded. At that time there was no agreement for those
indications (class 2 indications), as was formulated in the
1999 Dutch pacing guidelines [18, 19].
The difference in implantation rates between provinces
does not seem to be related to differences in the age of
the population. Some provinces with a higher implanta-
tion rate have a younger population than provinces with
a lower implantation rate. In some provinces one or two
hospitals are responsible for more than half of the implan-
tations performed in that province. These hospitals could
be ‘hot spots’ that treat patients from a wider area than the
province alone. When done on a regular basis, pacemaker
implantation is safe. However, operator volume appears to
count when it comes to quality of care. A concentration of
procedures in centres where cardiologists implant at least
50 devices per year has therefore been suggested previously
[20].
Sick sinus syndrome and heart block were the major in-
dications for pacemaker implantation. Sick sinus syndrome
was significantly predominant in women. This could be
attributed to the fact that sick sinus syndrome occurs more
often in female than in male individuals [21]. The indica-
tions for pacemaker implantations found in our study are in
line with the major indications in other European countries.
During the early 1990s physiological pacing and the use
of adaptive pacing frequencies with dual chamber systems
(DDD(R)) were increasingly used compared with single
chamber systems (VVI(R)). From the more recent World
Society of Arrhythmias (WSA) surveys it appeared that in-
deed virtually all countries had increased percentages of
DDDR pacemaker implantations [15–17, 22]. A modest
increase of implantation for bundle branch block is visible
over the period 2000 to 2005, especially in men. This may
be explained in part by the increased use of biventricular
pacemakers for cardiac resynchronisation therapy. CRT de-
vices with ICD function (CRT-D) were not registered in
this database and are therefore not included in the current
analysis. Internationally, an increase of non-bradyarrhyth-
mic indications for cardiac pacing was projected, however
remained a minor indication with approximately 5 % or less
in most countries [15–17, 22]. In the Netherlands this per-
centage remained less than 5 % for a long time, but started
increasing in the early 2000s.
Limitations
An important limitation of the data is that registration lies
in many hands, which facilitates registration errors such
as typographical errors and duplicate registrations of pa-
tients transferred to another hospital. We removed these
duplicates whenever possible. However, some may have
been overlooked due to unavailability of highly detailed
patient-related data needed to distinguish duplicate records.
Nevertheless, 99 % of all implantations are registered [12,
18] and the data provide useful information; therefore, er-
rors are expected to be random with regard to indication
and pacemaker properties. In contrast to the ECG data
and symptoms, information on aetiology is absent in most
cases. However, in cardiology practice it appears to be very
difficult to establish the precise cause of cardiac or non-car-
diac disease that elicits rhythm or conduction disturbances.
Additionally, the type of pacemaker was registered at base-
line, but the actual setting could have been changed after
implantation or during follow-up.
Conclusion
Maintaining a registry for implantable devices can serve
many purposes. It provides insight into the patient popula-
tion, trends regarding devices used and perhaps even more
important: tracking and tracing of products in case of fail-
ures and recalls. Over the years the SPRN registry has
provided input for several of these purposes, the most im-
portant being the tracking and tracing of patients in case of
recalled devices. As some risks of implantable devices will
only become apparent during the actual clinical use after
marketing of the device, registries can serve a purpose in
identifying those as well.
In conclusion, analysis of the SPRN database has shown
that the frequency of first implantation of pacemakers has
steadily increased in the Netherlands and that trends in in-
dications for implantation and pacemaker type are in line
with other European countries.
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